Overview

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and and Baricitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, cyclophosphamide/etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors

Phase:

PHASE2

Details

Lead Sponsor:

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Treatments:

Abatacept
baricitinib
Cyclophosphamide
vedolizumab